The NCCN Oncology Research Program (ORP) nears the $20 million mark in total funding and enhances its current model to include funding for therapeutics in development as well as those already FDA-approved. The ORP draws on the expertise of investigators at 21 of the world’s leading cancer centers (NCCN Member Institutions) in order to advance therapeutic options for patients with cancer.
April 29, 2009
FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) recently marked its 10 year anniversary by announcing that it is close to achieving $20 million in total funding since the inception of the program. The ORP also announced a new research model that expands their research focus into drugs in development to complement the current model that provides funding for FDA-approved therapies.
“NCCN is thrilled to have attained nearly $20 million in funding for research that seeks to reduce cancer-related deaths and improve the quality of life for patients by advancing innovative therapies through clinical trials at NCCN Member Institutions,” says William T. McGivney, PhD, Chief Executive Officer, NCCN. “By expanding the program to include therapies in development, NCCN continues to enhance its role in furthering the science of oncology by offering a more comprehensive set of services.”
The NCCN ORP is organized to obtain funding to support investigator-initiated trials at NCCN Member Institutions that explore new avenues of clinical investigation to answer important scientific questions. Studies evaluate innovative combinations and sequencing regimens of drugs, mechanisms of action of specific agents, drug resistance, and extended uses for specific agents.
In addition to developing a successful model to support research enterprises at NCCN Member Institutions, the NCCN ORP organizes scientific advisory boards to evaluate potential uses of promising agents and provide expert advice on the best avenues of research to pursue.
The NCCN ORP was developed in 1999 and was initially named the Clinical Trials Network before evolving into the Oncology Research Program in 2005. By building a centralized clinical trials infrastructure in which supporters have access to premier experts and investigators at 21 of the world’s leading cancer centers, NCCN looks to continue to provide patients with promising treatment through state-of-the-art clinical research trials.
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.